Group responds to public consultation and proposes changes including an increase in the THC limit and expansion of cannabinoid manipulation

In an unprecedented decision, the São Paulo State Court of Justice (TJ-SP) authorized a Compounding Pharmacy to compound and dispense medicinal products and phytopharmaceuticals based on Cannabis sativa. The said decision is still subject to appeal in the higher courts.

New regulation simplifies registration and expands the use of biodiversity in herbal medicines, as soon as cannabis products are classified as medicines, they must comply with these standards.

Proposal authorizes companies to cultivate plants with up to 0.3% THC exclusively for the production of medicinal inputs, but experts warn of the technical unfeasibility of the limit in a tropical climate

Pharmaceutical company Ephar has obtained registration for its Cannabidiol in two concentrations, 50 mg/mL and 100 mg/mL, which will be marketed in a low THC content drop solution.

In an interview with the CB.Poder program of Correio Brasiliense, conducted by journalists Adriana Bernardes and Sibele Negromonte, Leandro Safatle, acting CEO of Anvisa, detailed the behind-the-scenes and expectations regarding the new regulation of medicinal cannabis and research in Brazil

Proposal aims to regulate the performance of non-profit entities in a controlled experimental environment, using the Regulatory Sandbox model to comply with STJ decision

According to Marcelo Polacow Bisson, excluding pharmacies' manipulation leads to lack of assistance; Anvisa's proposed text on the Cannabis regulation is also criticized for bypassing procedural rites

How the pharmaceutical industry ensures quality and safety in cannabis-based products sold in Brazil

Gustavo Palhares believes that regulatory revision can relax prescriptions, expand access, and raise technical requirements in the medicinal cannabis sector

Curitiba welcomes its first exclusive medicinal cannabis pharmacy, in a market that grew from R$ 38.5 million in 2022 to R$ 237.8 million in 2025, while Paraná accounts for only 2.4% of sales, indicating great potential in the state with 11 million inhabitants

Projections indicate accelerated growth of the medicinal cannabis market by 2034, driven by regulatory changes and expanded therapeutic applications

The sector reached growth of over 65% in 2024; the medical cannabis market reached R$ 345 million in pharmacies

Agency defines a modular strategy for cannabis cultivation, establishing distinct rules for patient associations, research, and industry

Lecture led by specialist will address scientific updates, clinical use, and regulation of cannabinoid therapies in Dentistry during the event in São Paulo

Traveling at year-end and using medical cannabis? Learn what documents are required, how to transport the medication, and what precautions to take in Brazil and abroad.

The pharmaceutical company Farmausa Life Science has obtained registration for its Cannabidiol in two concentrations, 20 mg/mL and 100 mg/mL, with low THC content

Cannten's extract with 71.33 mg/mL expands medicinal treatment options in the country and receives authorization for commercialization

Extract from the company Endogen expands the portfolio of options for medicinal treatments and already has sanitary authorization for commercialization

Event will address rules that directly impact the herbal medicine sector and cannabis-based products; participation is open to the public.